Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice
HER2/neu is an oncogene amplified and over-expressed in 20-30% of breast adenocarcinomas. Treatment with the humanized monoclonal antibody trastuzumab has shown efficacy in combination with cytotoxic agents, although resistance occurs over time. Novel approaches are needed to further increase antibo...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2011-05, Vol.29 (20), p.3646-3654 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3654 |
|---|---|
| container_issue | 20 |
| container_start_page | 3646 |
| container_title | Vaccine |
| container_volume | 29 |
| creator | Orlandi, Francesca Guevara-Patiño, José A Merghoub, Taha Wolchok, Jedd D Houghton, Alan N Gregor, Polly D |
| description | HER2/neu is an oncogene amplified and over-expressed in 20-30% of breast adenocarcinomas. Treatment with the humanized monoclonal antibody trastuzumab has shown efficacy in combination with cytotoxic agents, although resistance occurs over time. Novel approaches are needed to further increase antibody efficacy. In this study, we provide evidence in a mouse breast cancer therapeutic tumor model that the combination of active immunization with a modified HER2/neu DNA vaccine and passive infusion of an anti-HER2/neu monoclonal antibody leads to significant regression of established tumors. Our data indicate that combination therapy with a HER2/neu DNA vaccine and trastuzumab may have clinical activity in breast cancer patients. |
| doi_str_mv | 10.1016/j.vaccine.2011.03.017 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_874192453</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X11003690</els_id><sourcerecordid>864192586</sourcerecordid><originalsourceid>FETCH-LOGICAL-c533t-3849eac54d216da99678496ce48178f8d2faf3dbd69e808490264f7fdc3d290a3</originalsourceid><addsrcrecordid>eNqFktGK1DAUhoso7rj6CGpAxKvOnjRt2t4oy7i6wqLguuBdyCSnQ8Y2qUk7MD6Iz2tqqwt7s1eBnO_858_5kyTPKawpUH62Xx-kUsbiOgNK18DWQMsHyYpWJUuzglYPkxVkPE9zCt9Pkich7AGgYLR-nJxkNGdFDsUq-b1x3dZYORhniWsI9mZwPaauH0xnfqEm7z-fk3nUDEmrSS9DMAckxjZjWDo7Z51qnZVtRAazdfpI5E4aGwZyefE1O7M4khalDmRwZOtRxsIwds4TjzuP4a-QsaQzCp8mjxrZBny2nKfJzYeLb5vL9OrLx0-b86tUFYwNKavyGqUqcp1RrmVd8zLecIV5RcuqqXTWyIbpreY1VhBL00aastGK6awGyU6TN7Nu793PEcMgOhMUtq206MYgqjKndZbHYfeSfCKLikfy1R1y70Yf9xIE5ZHIq7qCSBUzpbwLwWMjem866Y-CgpgSFnuxJCymhAUwEROOfS8W9XHbof7f9S_SCLxeABmUbBsvrTLhlssp5xmbDLycuUY6IXc-MjfXcVIBQFkN5fSQdzOBMYGDQS-CMmgVauNRDUI7c6_Zt3cUVGusibZ-4BHD7V5EyASI6yme6b9SCsB4DewPEYzl3g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1625848980</pqid></control><display><type>article</type><title>Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Orlandi, Francesca ; Guevara-Patiño, José A ; Merghoub, Taha ; Wolchok, Jedd D ; Houghton, Alan N ; Gregor, Polly D</creator><creatorcontrib>Orlandi, Francesca ; Guevara-Patiño, José A ; Merghoub, Taha ; Wolchok, Jedd D ; Houghton, Alan N ; Gregor, Polly D</creatorcontrib><description>HER2/neu is an oncogene amplified and over-expressed in 20-30% of breast adenocarcinomas. Treatment with the humanized monoclonal antibody trastuzumab has shown efficacy in combination with cytotoxic agents, although resistance occurs over time. Novel approaches are needed to further increase antibody efficacy. In this study, we provide evidence in a mouse breast cancer therapeutic tumor model that the combination of active immunization with a modified HER2/neu DNA vaccine and passive infusion of an anti-HER2/neu monoclonal antibody leads to significant regression of established tumors. Our data indicate that combination therapy with a HER2/neu DNA vaccine and trastuzumab may have clinical activity in breast cancer patients.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2011.03.017</identifier><identifier>PMID: 21435405</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>adenocarcinoma ; Adenocarcinoma - immunology ; Adenocarcinoma - therapy ; Allergy and Immunology ; Animals ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - immunology ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Antigens ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - immunology ; Biological and medical sciences ; Breast cancer ; breast neoplasms ; Cancer therapies ; Cancer Vaccines - administration & dosage ; Cancer Vaccines - immunology ; Chemotherapy ; Clinical trials ; Cytokines ; cytotoxicity ; Deoxyribonucleic acid ; DNA ; DNA vaccine ; Epitopes - immunology ; Female ; gene overexpression ; HER2/neu ; Immunization ; Immunotherapy ; Lymphocytes ; Lymphocytes, Tumor-Infiltrating - immunology ; Mammary Neoplasms, Experimental - immunology ; Mammary Neoplasms, Experimental - therapy ; Medical research ; Medical sciences ; Melanoma ; Metastasis ; Mice ; Mice, Inbred BALB C ; monoclonal antibodies ; Mutagenesis, Site-Directed ; Mutation ; oncogenes ; patients ; Peptides ; Receptor, ErbB-2 - immunology ; recombinant vaccines ; remission ; Signal transduction ; Skin cancer ; Trastuzumab ; Tumors ; vaccination ; Vaccines ; Vaccines, DNA - administration & dosage ; Vaccines, DNA - immunology</subject><ispartof>Vaccine, 2011-05, Vol.29 (20), p.3646-3654</ispartof><rights>Elsevier Ltd</rights><rights>2011 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited May 9, 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c533t-3849eac54d216da99678496ce48178f8d2faf3dbd69e808490264f7fdc3d290a3</citedby><cites>FETCH-LOGICAL-c533t-3849eac54d216da99678496ce48178f8d2faf3dbd69e808490264f7fdc3d290a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1625848980?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,778,782,3539,27911,27912,45982,64370,64372,64374,72224</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24166230$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21435405$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Orlandi, Francesca</creatorcontrib><creatorcontrib>Guevara-Patiño, José A</creatorcontrib><creatorcontrib>Merghoub, Taha</creatorcontrib><creatorcontrib>Wolchok, Jedd D</creatorcontrib><creatorcontrib>Houghton, Alan N</creatorcontrib><creatorcontrib>Gregor, Polly D</creatorcontrib><title>Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>HER2/neu is an oncogene amplified and over-expressed in 20-30% of breast adenocarcinomas. Treatment with the humanized monoclonal antibody trastuzumab has shown efficacy in combination with cytotoxic agents, although resistance occurs over time. Novel approaches are needed to further increase antibody efficacy. In this study, we provide evidence in a mouse breast cancer therapeutic tumor model that the combination of active immunization with a modified HER2/neu DNA vaccine and passive infusion of an anti-HER2/neu monoclonal antibody leads to significant regression of established tumors. Our data indicate that combination therapy with a HER2/neu DNA vaccine and trastuzumab may have clinical activity in breast cancer patients.</description><subject>adenocarcinoma</subject><subject>Adenocarcinoma - immunology</subject><subject>Adenocarcinoma - therapy</subject><subject>Allergy and Immunology</subject><subject>Animals</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antigens</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - immunology</subject><subject>Biological and medical sciences</subject><subject>Breast cancer</subject><subject>breast neoplasms</subject><subject>Cancer therapies</subject><subject>Cancer Vaccines - administration & dosage</subject><subject>Cancer Vaccines - immunology</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Cytokines</subject><subject>cytotoxicity</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>DNA vaccine</subject><subject>Epitopes - immunology</subject><subject>Female</subject><subject>gene overexpression</subject><subject>HER2/neu</subject><subject>Immunization</subject><subject>Immunotherapy</subject><subject>Lymphocytes</subject><subject>Lymphocytes, Tumor-Infiltrating - immunology</subject><subject>Mammary Neoplasms, Experimental - immunology</subject><subject>Mammary Neoplasms, Experimental - therapy</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Melanoma</subject><subject>Metastasis</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>monoclonal antibodies</subject><subject>Mutagenesis, Site-Directed</subject><subject>Mutation</subject><subject>oncogenes</subject><subject>patients</subject><subject>Peptides</subject><subject>Receptor, ErbB-2 - immunology</subject><subject>recombinant vaccines</subject><subject>remission</subject><subject>Signal transduction</subject><subject>Skin cancer</subject><subject>Trastuzumab</subject><subject>Tumors</subject><subject>vaccination</subject><subject>Vaccines</subject><subject>Vaccines, DNA - administration & dosage</subject><subject>Vaccines, DNA - immunology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFktGK1DAUhoso7rj6CGpAxKvOnjRt2t4oy7i6wqLguuBdyCSnQ8Y2qUk7MD6Iz2tqqwt7s1eBnO_858_5kyTPKawpUH62Xx-kUsbiOgNK18DWQMsHyYpWJUuzglYPkxVkPE9zCt9Pkich7AGgYLR-nJxkNGdFDsUq-b1x3dZYORhniWsI9mZwPaauH0xnfqEm7z-fk3nUDEmrSS9DMAckxjZjWDo7Z51qnZVtRAazdfpI5E4aGwZyefE1O7M4khalDmRwZOtRxsIwds4TjzuP4a-QsaQzCp8mjxrZBny2nKfJzYeLb5vL9OrLx0-b86tUFYwNKavyGqUqcp1RrmVd8zLecIV5RcuqqXTWyIbpreY1VhBL00aastGK6awGyU6TN7Nu793PEcMgOhMUtq206MYgqjKndZbHYfeSfCKLikfy1R1y70Yf9xIE5ZHIq7qCSBUzpbwLwWMjem866Y-CgpgSFnuxJCymhAUwEROOfS8W9XHbof7f9S_SCLxeABmUbBsvrTLhlssp5xmbDLycuUY6IXc-MjfXcVIBQFkN5fSQdzOBMYGDQS-CMmgVauNRDUI7c6_Zt3cUVGusibZ-4BHD7V5EyASI6yme6b9SCsB4DewPEYzl3g</recordid><startdate>20110509</startdate><enddate>20110509</enddate><creator>Orlandi, Francesca</creator><creator>Guevara-Patiño, José A</creator><creator>Merghoub, Taha</creator><creator>Wolchok, Jedd D</creator><creator>Houghton, Alan N</creator><creator>Gregor, Polly D</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>7TM</scope></search><sort><creationdate>20110509</creationdate><title>Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice</title><author>Orlandi, Francesca ; Guevara-Patiño, José A ; Merghoub, Taha ; Wolchok, Jedd D ; Houghton, Alan N ; Gregor, Polly D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c533t-3849eac54d216da99678496ce48178f8d2faf3dbd69e808490264f7fdc3d290a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>adenocarcinoma</topic><topic>Adenocarcinoma - immunology</topic><topic>Adenocarcinoma - therapy</topic><topic>Allergy and Immunology</topic><topic>Animals</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antigens</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - immunology</topic><topic>Biological and medical sciences</topic><topic>Breast cancer</topic><topic>breast neoplasms</topic><topic>Cancer therapies</topic><topic>Cancer Vaccines - administration & dosage</topic><topic>Cancer Vaccines - immunology</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Cytokines</topic><topic>cytotoxicity</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>DNA vaccine</topic><topic>Epitopes - immunology</topic><topic>Female</topic><topic>gene overexpression</topic><topic>HER2/neu</topic><topic>Immunization</topic><topic>Immunotherapy</topic><topic>Lymphocytes</topic><topic>Lymphocytes, Tumor-Infiltrating - immunology</topic><topic>Mammary Neoplasms, Experimental - immunology</topic><topic>Mammary Neoplasms, Experimental - therapy</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Melanoma</topic><topic>Metastasis</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>monoclonal antibodies</topic><topic>Mutagenesis, Site-Directed</topic><topic>Mutation</topic><topic>oncogenes</topic><topic>patients</topic><topic>Peptides</topic><topic>Receptor, ErbB-2 - immunology</topic><topic>recombinant vaccines</topic><topic>remission</topic><topic>Signal transduction</topic><topic>Skin cancer</topic><topic>Trastuzumab</topic><topic>Tumors</topic><topic>vaccination</topic><topic>Vaccines</topic><topic>Vaccines, DNA - administration & dosage</topic><topic>Vaccines, DNA - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Orlandi, Francesca</creatorcontrib><creatorcontrib>Guevara-Patiño, José A</creatorcontrib><creatorcontrib>Merghoub, Taha</creatorcontrib><creatorcontrib>Wolchok, Jedd D</creatorcontrib><creatorcontrib>Houghton, Alan N</creatorcontrib><creatorcontrib>Gregor, Polly D</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Nucleic Acids Abstracts</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Orlandi, Francesca</au><au>Guevara-Patiño, José A</au><au>Merghoub, Taha</au><au>Wolchok, Jedd D</au><au>Houghton, Alan N</au><au>Gregor, Polly D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2011-05-09</date><risdate>2011</risdate><volume>29</volume><issue>20</issue><spage>3646</spage><epage>3654</epage><pages>3646-3654</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>HER2/neu is an oncogene amplified and over-expressed in 20-30% of breast adenocarcinomas. Treatment with the humanized monoclonal antibody trastuzumab has shown efficacy in combination with cytotoxic agents, although resistance occurs over time. Novel approaches are needed to further increase antibody efficacy. In this study, we provide evidence in a mouse breast cancer therapeutic tumor model that the combination of active immunization with a modified HER2/neu DNA vaccine and passive infusion of an anti-HER2/neu monoclonal antibody leads to significant regression of established tumors. Our data indicate that combination therapy with a HER2/neu DNA vaccine and trastuzumab may have clinical activity in breast cancer patients.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>21435405</pmid><doi>10.1016/j.vaccine.2011.03.017</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2011-05, Vol.29 (20), p.3646-3654 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_874192453 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| subjects | adenocarcinoma Adenocarcinoma - immunology Adenocarcinoma - therapy Allergy and Immunology Animals Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - immunology Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antigens Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - immunology Biological and medical sciences Breast cancer breast neoplasms Cancer therapies Cancer Vaccines - administration & dosage Cancer Vaccines - immunology Chemotherapy Clinical trials Cytokines cytotoxicity Deoxyribonucleic acid DNA DNA vaccine Epitopes - immunology Female gene overexpression HER2/neu Immunization Immunotherapy Lymphocytes Lymphocytes, Tumor-Infiltrating - immunology Mammary Neoplasms, Experimental - immunology Mammary Neoplasms, Experimental - therapy Medical research Medical sciences Melanoma Metastasis Mice Mice, Inbred BALB C monoclonal antibodies Mutagenesis, Site-Directed Mutation oncogenes patients Peptides Receptor, ErbB-2 - immunology recombinant vaccines remission Signal transduction Skin cancer Trastuzumab Tumors vaccination Vaccines Vaccines, DNA - administration & dosage Vaccines, DNA - immunology |
| title | Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T21%3A42%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combination%20of%20epitope-optimized%20DNA%20vaccination%20and%20passive%20infusion%20of%20monoclonal%20antibody%20against%20HER2/neu%20leads%20to%20breast%20tumor%20regression%20in%20mice&rft.jtitle=Vaccine&rft.au=Orlandi,%20Francesca&rft.date=2011-05-09&rft.volume=29&rft.issue=20&rft.spage=3646&rft.epage=3654&rft.pages=3646-3654&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2011.03.017&rft_dat=%3Cproquest_cross%3E864192586%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1625848980&rft_id=info:pmid/21435405&rft_els_id=S0264410X11003690&rfr_iscdi=true |